Title:
急性心筋梗塞中の心筋傷害の低減方法
Document Type and Number:
Japanese Patent JP4077030
Kind Code:
B2
Abstract:
PCT No. PCT/NL94/00208 Sec. 371 Date Apr. 2, 1996 Sec. 102(e) Date Apr. 2, 1996 PCT Filed Aug. 31, 1994 PCT Pub. No. WO95/06479 PCT Pub. Date Mar. 9, 1995A therapeutic or prophylactic treatment method of acute myocardial infarction, comprising administering exogenous C1-esterase inhibitor, alone or in combination with other drugs, to a patient with acute myocardial infarction or to a patient at risk for acute myocardial infarction. The treatment inhibits the inflammatory reaction, more specifically the activation of the complement system, which occurs in the course of acute myocardial infarction. The C1-esterase inhibitor may include C1-esterase inhibitor purified from plasma or other biological materials, or recombinant C1-esterase inhibitor, or recombinant variants derived therefrom, or recombinant constructs of other inhibitors having a specificity similar to C1-esterase inhibitor.
More Like This:
Inventors:
Helmens, Willem Theodor
Hutsk, Cornelis Erik
Hutsk, Cornelis Erik
Application Number:
JP50804995A
Publication Date:
April 16, 2008
Filing Date:
August 31, 1994
Export Citation:
Assignee:
Stayhitting Central Laboratorium Van de Bled Transfancy Deanst van Het Nederlandse Rode Kluis
International Classes:
A61K38/48; A61K38/46; A61K38/55; A61K38/54; A61K38/57; A61P9/08; A61P9/10; A61P29/00
Domestic Patent References:
| JP5504053A | ||||
| JP2502542A | ||||
| JP59044320A | ||||
| JP5503001A |
Foreign References:
| WO1992022320A1 |
Other References:
Eldering E., Characterization of recombinant C1 inhibitor P1 variants, The Journal of biological chemistry, 1992年, Vol.267, No.10, p.7013-7020
Eldering E., Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils, The Journal of clinical investigation, 1993年, Vol.91, No.3, p.1035-1043
Davis A. E.III, C1 inhibitor hinge region mutations produce dysfunction by different mechanisms, Nature Genetics, 1992年, Vol.1, No.5, p.354-358
今堀和友, C1,生化学事典 第2版, 1990年, p.570
WEISMAN H.F., Soluble Human Complement Receptor Type 1: In Vivo Inhibitorof Complement Suppressing Post-Ischemic M, Science, 1990年, Vol.249, p.146-151
SMITH III E.F., Reduction of myocardial reperfusion injury with human solble complement receptor type 1 (BRL 55730), European Journal of Pharmacology, 1993年, Vol.236, p.477-481
今堀和友 山川民夫, 生化学辞典(第2版), 1990年, p.570,1256,1257
守内郁夫, 急性心筋梗塞プライマリケアのポイント, medicina, 1992年, Vol.29, No.7, p.1220-1221
玉井秀男,プライマリケアでの静注法, medicina, 1990年, Vol.27, No.1, p.60-61
葛谷 恒彦,フリーラジカル, medicina, 1990年, Vol.27, No.1, p.18-20
Eldering E., Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils, The Journal of clinical investigation, 1993年, Vol.91, No.3, p.1035-1043
Davis A. E.III, C1 inhibitor hinge region mutations produce dysfunction by different mechanisms, Nature Genetics, 1992年, Vol.1, No.5, p.354-358
今堀和友, C1,生化学事典 第2版, 1990年, p.570
WEISMAN H.F., Soluble Human Complement Receptor Type 1: In Vivo Inhibitorof Complement Suppressing Post-Ischemic M, Science, 1990年, Vol.249, p.146-151
SMITH III E.F., Reduction of myocardial reperfusion injury with human solble complement receptor type 1 (BRL 55730), European Journal of Pharmacology, 1993年, Vol.236, p.477-481
今堀和友 山川民夫, 生化学辞典(第2版), 1990年, p.570,1256,1257
守内郁夫, 急性心筋梗塞プライマリケアのポイント, medicina, 1992年, Vol.29, No.7, p.1220-1221
玉井秀男,プライマリケアでの静注法, medicina, 1990年, Vol.27, No.1, p.60-61
葛谷 恒彦,フリーラジカル, medicina, 1990年, Vol.27, No.1, p.18-20
Attorney, Agent or Firm:
Heikichi Odashima